Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Other Working Capital Changes (2016 - 2025)

Wave Life Sciences' Other Working Capital Changes history spans 11 years, with the latest figure at $2.9 million for Q4 2025.

  • For Q4 2025, Other Working Capital Changes rose 12.71% year-over-year to $2.9 million; the TTM value through Sep 2025 reached -$326000.0, down 100.59%, while the annual FY2024 figure was $3.2 million, 94.06% down from the prior year.
  • Other Working Capital Changes reached $2.9 million in Q4 2025 per WVE's latest filing, up from $802000.0 in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $126.4 million in Q1 2023 to a low of -$128.9 million in Q2 2023.
  • Average Other Working Capital Changes over 5 years is $2.7 million, with a median of $399000.0 recorded in 2021.
  • Peak YoY movement for Other Working Capital Changes: soared 21800.0% in 2022, then tumbled 6169.55% in 2023.
  • A 5-year view of Other Working Capital Changes shows it stood at $3.1 million in 2021, then tumbled by 263.53% to -$5.1 million in 2022, then surged by 1160.04% to $54.5 million in 2023, then plummeted by 95.3% to $2.6 million in 2024, then increased by 12.71% to $2.9 million in 2025.
  • Per Business Quant, the three most recent readings for WVE's Other Working Capital Changes are $2.9 million (Q4 2025), $802000.0 (Q3 2025), and -$3.6 million (Q2 2025).